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Abstract  In  microcirculation  disorders,  the  therapeutic 
apheresis  seems  to  have  two  different  effects.  The  first, 
achieved  after  only  a  few  sessions,  is  acute,  consist-
ing  of  drastic  reduction  of  blood  viscosity  and  obtained 
with  the  use  of  low-density  lipoprotein  (LDL)  apheresis, 
rheopheresis, or fibrinogen apheresis. The second effect is 
long  term,  or  chronic,  and  needs  to  be  evaluated  after  a 
long course of  treatment. The mechanisms underlying  the 
chronic  effect  are  still  objects of debate  and  take  into  ac-
count  the  pleiotropic  effects  of  apheresis.  However,  it  is 
likely  that  the  acute  effect  of  apheresis mainly  influences 
the functional components of the vascular damage, and so 
the derived  rheological benefit might  last only  for a  short 
period. The chronic effect, on the contrary, by acting on the 









the  number  of  apheresis  sessions  considered  necessary  to 






rapeutic  apheresis  and  its  capacity  to  reduce  the  concen-
trations  of  some  plasma  proteins  closely  connected  with 
hemorheology [2].
However,  it  is  now  becoming  evident  that  long-term 
treatment with therapeutic apheresis, especially chronic the-
rapy with low-density lipoprotein (LDL) apheresis in pati-










Therefore,  it  seems  likely  that  therapeutic  apheresis  is 
capable  of  achieving  two  different  effects:  a  rapid  effect, 
also called acute effect  that  takes place very rapidly, even 




















The  acute  effect may  be  attributed  to  the  reduction  in 










The  greater  importance  attributed  to  the  reduction  of 




option  for  SHL,  demonstrating  that  two  sessions  of  this 
apheresis strategy within 3 days lasting for about 2 h each 
could  be  used  to  replace  a  10-day  infusion  regimen. Ull-
rich and colleagues [5] confirmed the role of fibrinogen in 
improving hemorheology by means of fibrinogen apheresis, 
which  they  used  as  a  therapeutic  procedure  for  the  treat-
ment of SHL.  In  this  study also,  the authors administered 
only few sessions of apheresis, three at the most. The main 
auditory improvement was evident directly after the end of 







optic  nerve  head,  due  to  the  involvement  of  the  posterior 
ciliary  arteries.  Despite  traditional  treatment,  the  disease 
has  a  substantially  stable  course  over  time  and may  even 
get worse. Therefore, NAION has  been  an  excellent field 
of application to verify the efficacy of therapeutic aphere-
sis, much better than SHL where a spontaneous recovery is 
frequently observed.  In  two pilot  studies,  the use of  three 
sessions of LDL apheresis determined a clear improvement 
in  the  functional data  for  the affected eyes  [6, 7].  In  fact, 
the scotomatous portion of the visual field regressed already 
after the first session of LDL apheresis and further regressed 















have  in  common  a  rapid  drop  in macromolecule  concen-
trations that has an effect on the blood rheology. We know 
that  hemorheology  is  determined  by  the  viscosity  of  the 
plasma and the whole blood and by the erythrocyte defor-
mability  and  tendency  to  aggregate.  Otto  and  colleagues 





if  it  accounts  for  only  4%  of  the  plasma  protein  content. 
Moreover, fibrinogen has often been described as the most 
important  protein  in  physiological  and  pathological  red 












lowering  the  concentrations  of  these macromolecules,  the 
LDL  apheresis,  rheopheresis,  or  fibrinogen  apheresis  red-
uce the blood viscosity and therefore the resistance to flow, 
according  to  the Hagen–Poiseuille  law. For  these  reasons, 
these  three procedures could have an effect—I would  say 
a  rapid  effect—on  the  clinical  picture  of microcirculation 






sing  the  conditions  of  a  group  of  patients  6 months  after 
they had been treated with LDL apheresis [13]. The mean 
deviation of the visual field resulted statistically improved 




















Nevertheless,  long-term  treatment  with  therapeutic  aphe-
resis  has  been  shown  to  induce  a  suppression  of  the  pro-
gression  of  atherosclerotic  lesions  and  eventually  also  a 
regression of atherosclerotic lesions, thus acting to improve 

















to  consider  a  possible  influence  of  LDL  apheresis  on  the 
number  of  circulating  endothelial  progenitor  cells,  which 









then  stopping  the  apheresis  in  one  patient  and  continuing 
the procedure in the other one, in order to establish the best 
timetable for this therapeutic approach. The patients under-
went 22  sessions of  rheopheresis over 4 months;  then  the 
first patient continued the apheresis at the rate of one session 
a week for another year while the second patient remained 














In conclusion, what we still need  to explore  further  is  the 
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